Molecular Formula | C34H34Cl2F3NO3
|
Molar Mass | 632.55 |
Solubility | DMSO : 150 mg/mL (237.14 mM; ultrasonic and warming and heat to 60°C) |
Storage Condition | -20°C |
In vitro study | RGX-104, an orally administered LXR agonist, potently induces ApoE expression, resulting in endogenous immune-mediated antitumor activity. RGX-104 drives anti-tumor immune responses by modulating the abundance and activity of myeloid-derived suppressor cells and dendritic cells. |
In vivo study | In several syngenic xenograft tumor models, RGX-104 monotherapy elicits a tumor response, including melanoma, ovarian cancer, lung cancer, and glioblastoma multiforme. This antitumor activity via activation of LXR is associated with constitutive upregulation of ApoE expression. |